Views & Analysis Exclusive: Brexit likely to cause long-term damage to UK pha... Exclusive survey finds concerns about future of UK pharma industry
Debates & Insight Sponsored Finding a cure: Getting the best Brexit deal for Britain’s l... Four months have now elapsed since the UK voted to leave the EU.
News GSK pursues $10.6bn takeover of cancer biotech Nuvalent GSK is preparing for its biggest acquisition in more than 10 years, agreeing to buy cancer drug developer Nuvalent for $10.6 billion.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
